The bone mass density in postmenopausal women using hormonal replacement therapy in relation to polymorphism in vitamin D receptor and estrogen receptor genes

Brodowska, Agnieszka; Starczewski, Andrzej; Brodowski, Jacek; Szydłowska, Iwona; Nawrocka-Rutkowska, Jolanta

doi:10.1080/09513590802630138

Cited by 9 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effectiveness of EP therapy is mostly determined by the ability to respond to hormonal substitution. This was confirmed both in studies 17 – 19 and in experiments by other authors 20 – 22 . All suggesting the involvement of the ER-α gene polymorphisms in determining response to oestroprogestagen therapy.…”

Section: Introductionsupporting

confidence: 85%

The influence of ESR1 polymorphisms on selected hormonal, metabolic and mineral balance markers in women with hyperandrogenism

Uzar

Bogacz

Sowińska-Przepiera

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Hyperandrogenism is the most common endocrine disorder in women, characterized by an imbalance in normal estrogen and androgen levels in the blood. Androgens influence bone mineral density, body mass composition, muscle mass, mental state, and the regulation of sexual function.. The aim of the study was to assess the effect of estrogen receptor α gene (ESR1) polymorphisms on selected markers of bone metabolism and hormonal parameters in women with hyperandrogenism. The study group included 80 young women with hyperandrogenism who underwent measurements of bone mineral density (BMD), and determination of hormonal and metabolic parameters. Enzyme immunoassays were used to measure leptin, sRANKL (soluble receptor activator of nuclear factor-kB ligand), osteoprotegerin and 25-OH vitamin D total levels. An analysis of ESR1 gene polymorphisms was performed using the real-time PCR method. A relationship was demonstrated between the concentration of free estradiol (FEI) and the concentration of 17-OH-progesterone, and the ESR1 gene polymorphisms: rs3020314 (p = 0.031, p = 0.026 respectively) and rs1884051 (p = 0.033, p = 0.026 respectively). In conclusion, the ESR gene polymorphisms may be associated with hormonal disturbances in the concentration of estrogens and androgens, in hyperandrogenism in young women which may indirectly affect bone mineral density. However, no statistically significant relationships between the studied polymorphisms and the selected parameters of mineral metabolism have been demonstrated..

show abstract

Section: Introductionsupporting

confidence: 85%

The influence of ESR1 polymorphisms on selected hormonal, metabolic and mineral balance markers in women with hyperandrogenism

Uzar

Bogacz

Sowińska-Przepiera

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Studies on postmenopausal women subjected to hormonal therapy did not reveal which genetic variants of ER-α were predictors of poor BMD response to treatment. Depending on the study, either the xxPP haplotype [24, 25] or the XX genotype of XbaI [26, 27] and PP genotype of PvuII [27] were revealed as negative predictive factors. Other authors, in turn, did not observe significant relationships between ER-α and the response to hormonal treatment [28–30].…”

Section: Discussionmentioning

confidence: 99%

PvulI and Xbal polymorphism of estrogen receptor-α and the results of estroprogestagen therapy in girls with functional hypothalamic amenorrhea – preliminary study

Sowińska-Przepiera¹,

Syrenicz²,

Friebe³

et al. 2012

aoms

View full text Add to dashboard Cite

IntroductionThe aim of this study was the long-term prospective evaluation of the effects of estroprogestagen (EP) therapy on the bone mineral density (BMD) of girls with functional hypothalamic amenorrhea (FHA) carrying various PvuII and XbaI polymorphisms of ER-α.Material and methodsProspective observation included 84 FHA girls and 50 controls. The FHA patients were subjected to 4-year sequential therapy with 17β estradiol (2 mg from the 2nd to 25th day of the menstrual cycle) and dydrogesterone (10 mg from the 16th to the 25th day). Hormonal parameters, serum concentration of the bone fraction of alkaline phosphatase (BALP), urine concentration of cross-linked n-telopeptide of type I collagen (Ntx) and BMD were determined before and after the treatment.ResultsSix-month treatment resulted in a marked increase in estradiol (p = 0.001), testosterone and prolactin levels (p = 0.01 both) and a significant decrease in BALP and Ntx (p = 0.001 both). Patients with the PP polymorphism had significantly lower baseline BMD compared to carriers of other polymorphic variants of PvuII (p = 0.003). A significant increase in BMD was observed throughout the entire therapy period, with no significant differences in the yearly dynamics of BMD changes observed amongst various polymorphic variants and haplotypes of ER-α.ConclusionsThe EP therapy is effective in the treatment of BMD disorders associated with FHA, and treatment results do not depend on PvuII and XbaI polymorphisms of ER-α.

show abstract

“…[8][9][10]22 In another study, subjects with the PP and XX genotypes reveal decreased treatment efficiency. 5 To our knowledge, only one study has examined the relationship between ER polymorphisms and bone effects of phytoestrogen and found that low-dose isoflavone (30 mg d −1 ) supplementation is useful for maintaining BMD in premenopausal women with the XX genotype. 23 Our findings indicated that the association between the dietary phytoestrogen intake and BMD in postmenopausal women varied with ER polymorphisms.…”

Section: Food and Function Papermentioning

confidence: 99%

“…1,2 Phytoestrogen is a natural estrogen-like substance that is gaining increasing attention as a possible alternative to estrogen. 5,6 As the hub of estrogen action, the ER gene is an important candidate gene for exploring the etiological and therapeutic diversities of PMOP. Given the similar chemical structure of phytoestrogen to that of endogenous estrogen, it can bind to estrogen receptors (ERs) and produce varying estrogenic effects.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association between dietary phytoestrogen intake and bone mineral density varied with estrogen receptor alpha gene polymorphisms in southern Chinese postmenopausal women

et al. 2015

View full text Add to dashboard Cite

show abstract

The bone mass density in postmenopausal women using hormonal replacement therapy in relation to polymorphism in vitamin D receptor and estrogen receptor genes

Cited by 9 publications

References 42 publications

The influence of ESR1 polymorphisms on selected hormonal, metabolic and mineral balance markers in women with hyperandrogenism

The influence of ESR1 polymorphisms on selected hormonal, metabolic and mineral balance markers in women with hyperandrogenism

PvulI and Xbal polymorphism of estrogen receptor-α and the results of estroprogestagen therapy in girls with functional hypothalamic amenorrhea – preliminary study

Association between dietary phytoestrogen intake and bone mineral density varied with estrogen receptor alpha gene polymorphisms in southern Chinese postmenopausal women

Contact Info

Product

Resources

About